Mastitis remains one of the most persistent and costly health challenges in dairy production. It affects udder health, reduces milk quality, and limits overall herd performance.
Despite advances in herd management, producers continue to face production losses and added costs linked to the disease. As a result, the industry continues to focus on stronger prevention strategies, especially during high-risk periods like the transition into lactation.
Continued Focus on Prevention
Producers rely on a combination of practices to control mastitis. These include proper milking hygiene, clean housing, and close monitoring of cow health.
The dry-off period plays a critical role in prevention. During this stage, cows face a higher risk of new infections. For that reason, many herd health plans target this window for intervention.
At the same time, new tools continue to emerge in global markets.
New Vaccine Introduced in European Markets
Boehringer Ingelheim recently announced the launch of a mastitis vaccine, LENZELTA, in several European Union countries. The rollout begins in April 2026.
The vaccine targets two common mastitis pathogens: Staphylococcus aureus and Escherichia coli. It uses a two-dose protocol during the dry-off period. This timing helps support an early immune response and extends protection into early lactation, when cows are most vulnerable.
The product fits into existing herd health protocols. It also offers flexibility for veterinarians, with multiple vial sizes and an oil-free adjuvant system.
Ongoing Industry Priority
Mastitis control still depends on a whole-herd approach. Producers often work with veterinarians and nutritionists to refine transition cow management, udder health protocols, and overall herd performance.
New tools may expand prevention options over time. However, strong management practices remain the foundation of mastitis control.
The continued development of new technologies reflects the industry’s focus on reducing mastitis and improving herd health outcomes.
